Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.49 |
| ▸ | HTR2A | P28223 | 6/20 | 0.42 |
| ▸ | HTR2C | P28335 | 6/20 | 0.42 |
| ▸ | HTR2B | P41595 | 3/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001816 | 0.88 | TRPV1 (0.49) | TRPV1HTR2AHTR2CHTR2BBRD4 | |
| SCHEMBL4864851 | 0.84 | TRPV1 (0.52) | TRPV1HTR2AHTR2CHTR2BBRD4 | |
| SCHEMBL6001839 | 0.82 | ABCG2 (0.56) | TRPV1HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL4870857 | 0.82 | TRPV1 (0.54) | TRPV1HTR2AHTR2CHTR2BBRD4 | |
| SCHEMBL4728478 | 0.81 | TRPV1 (0.52) | TRPV1 | |
| SCHEMBL4871123 | 0.77 | TRPV1 (0.48) | TRPV1HTR2AHTR2CHTR2BBRD4 | |
| SCHEMBL12973478 | 0.75 | TRPV1 (0.52) | TRPV1HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL14086114 | 0.74 | TRPV1 (0.53) | TRPV1HTR2AHTR2C | |
| SCHEMBL4868546 | 0.74 | TRPV1 (0.55) | TRPV1HTR2AHTR2C | |
| SCHEMBL8251107 | 0.73 | TRPV1 (0.52) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128710-A1 | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof | ABBOTT LABORATORIES | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128710-A1 | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof | OPRL1, AVPR1A, AVPR2 | TRPV1 5/4885HTR2A 561/4885HTR2C 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.